Showing results (81-90 of 397) with videos related to
Sort By:
Pageof 40
American Heart Journal|October 31, 2006
Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarctionMette Elise Estensen, Aina Hognestad, Unni Syversen, et al.Controlled Clinical Trials|May 22, 2003
Toward protecting the safety of participants in clinical trialsRobert M Califf, Michael A Morse, Janet Wittes, et al.Clinical Trials (London, England)|November 11, 2005
Liability issues for data monitoring committee membersDavid L DeMets, Thomas R Fleming, Frank Rockhold, et al.European Heart Journal. Acute Cardiovascular Care|February 25, 2014
The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunctionEric S Ketchum, Kenneth Dickstein, John Kjekshus, et al.The American Journal of Cardiology|July 13, 2004
Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failureKenneth Dickstein, Hanka J De Voogd, Milutin P Miric, et al.European Heart Journal|August 8, 2006
Weight-change as a prognostic marker in 12 550 patients following acute myocardial infarction or with stable coronary artery diseaseLinn M A Kennedy, Kenneth Dickstein, Stefan D Anker, et al.European Heart Journal|June 9, 2009
Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary interventionStein Ørn, Cord Manhenke, Ole Jacob Greve, et al.Journal of the American College of Cardiology|December 6, 2005
Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patientsThor Ueland, John Kjekshus, Stig S Frøland, et al.European Heart Journal|March 21, 2009
C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarctionStein Ørn, Cord Manhenke, Thor Ueland, et al.Statistics in Biopharmaceutical Research|May 26, 2025
Monitoring overall survival in pivotal trials in indolent cancersThomas R Fleming, Lisa V Hampson, Bharani Bharani-Dharan, et al.Pageof 40